Assignee
ALENTIS THERAPEUTICS AG
CH·0 granted patents·5 pending applications·0 citations·filing 2023–2023
Top patents by PatentIndex Score
5 records- 0164US2025179170A1Use of anti-claudin-1 antibodies to increase t cell availabilityALENTIS THERAPEUTICS AG·Filed 2023·Application pending·0 cites
- 0260US2025326835A1Use of anti-claudin-1 antibodies to treat cholangiocarcinomaALENTIS THERAPEUTICS AG·Filed 2023·Application pending·0 cites
- 0360US2026055179A1Use of anti-claudin-1 antibodies to treat cholangiopathiesALENTIS THERAPEUTICS AG·Filed 2023·Application pending·0 cites
- 0459US2026015416A1Treatment of drug-resistant hepatocellular carcinomaALENTIS THERAPEUTICS AG·Filed 2023·Application pending·0 cites
- 0558US2026008845A1Biomarkers for fibrosis treatment using anti-claudin-1 antibodiesALENTIS THERAPEUTICS AG·Filed 2023·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when ALENTIS THERAPEUTICS AG files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →